香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 概 不 就 因 本 公 佈 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 本 公 佈 乃 根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則 第 13.43 條作出。 李氏大藥廠控股有限公司 ( 「 本公司 」 ) 董事會 ( 「 董 事 會 」 ) 謹此宣佈， 本 公 司 董 事 會 會 議 將 於 二 零 二 五 年 八 月 二 十 六 日 ( 星 期 二 ) 於 香 港 新 界 沙 田 香 港 科 學園第三期科技大道東 20E 大 樓 1 樓 舉行，為審議 ( 其 中 包 括 ) 並 批 准 ( 如 認 為 合 適 ) 刊 發 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 的 未 經 審 核 中 期 業 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 ...

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950.HK) announced that its subsidiary, China Oncology Medical Co., Ltd. (COF), received approval from the National Medical Products Administration (NMPA) for its cancer drug Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in mainland China [1] Group 1: Drug Approval and Clinical Trials - The approval is based on a Phase III, multi-center, randomized, double-blind, placebo-controlled clinical trial involving 54 centers, led by Professor Lu Shun from Shanghai Chest Hospital [1] - Results showed that patients treated with Socazolimab had a significantly improved overall survival of 13.90 months compared to 11.58 months in the placebo group, with no increase in safety risks associated with the treatment [1] Group 2: Drug Profile and Additional Trials - Socazolimab is a fully human anti-PD-L1 monoclonal antibody used for cancer treatment, and it has already been approved for first-line treatment of recurrent or metastatic cervical cancer and extensive-stage small cell lung cancer [1] - Another Phase III clinical trial for first-line treatment of persistent, recurrent, or metastatic cervical cancer is currently underway [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 本 公 佈 由 李 氏 大 藥 廠 控 股 有 限 公 司（「本公司」或「李氏大藥廠」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，於 二 零 二 五 年 七 月 二 十 九 日，本 公 司 附 屬 公 司 中 國 腫 瘤 醫 療 有 限 公 司（「COF」）腫 瘤 藥 物Socazolimab，已 獲 國 家 藥 品 監 督 管 理 局（「藥 監 局」）批 准 於 中 國 內 地 聯 合 化 療 用 於 廣 泛 期 小 細 胞 肺 癌（「ES-SCLC」）的 一 線 治 療。 此次批准是基於一項 ...

Group 1 - Deguote plans a major asset restructuring by acquiring control of Haowei Technology through a combination of share issuance and cash payment, along with raising supporting funds [3][9] - The transaction is expected to constitute a significant asset restructuring but will not result in a reverse listing [3] - Deguote's stock will be suspended from trading starting June 30, 2025, to ensure fair information disclosure and protect investor interests [3][9] Group 2 - Haowei Technology, formerly known as ZTE Soft Creation, was established in 2003 and has transitioned from a subsidiary of ZTE Corporation to being primarily owned by Nanjing Xiruang [5][6] - The company focuses on telecommunications support services and has been involved in cloud computing since its rebranding in 2018 [7] - Haowei Technology has provided digital transformation solutions to clients in over 80 countries and regions [7] Group 3 - Deguote is recognized as a "hidden leader" in the carbon black equipment manufacturing industry, specializing in energy-saving and environmental protection equipment [8] - The company has developed core technologies in various fields, holding 137 valid patents, including 29 invention patents [8] - In the fiscal year 2024, Deguote reported a revenue of 509 million yuan, a year-on-year increase of 64.21%, and a net profit of 96.71 million yuan, up 150.15% [8][9] Group 4 - In Q1 2025, Deguote achieved a revenue of 125 million yuan, a quarter-on-quarter growth of 41.57%, and a net profit of 23.35 million yuan, reflecting a significant increase of 1117.11% [9] - The company has signed a letter of intent with several investment firms for the asset acquisition, indicating strong interest from venture capital and private equity institutions [11]

Group 1 - Deguote plans to acquire control of Haowei Technology through a combination of share issuance and cash payment, with the transaction expected to constitute a major asset restructuring [1] - The transaction is still in the planning stage, with preliminary identified counterparties being major shareholders of Haowei Technology, including several limited partnerships [1] - Deguote's stock will be suspended from trading starting June 30, with a transaction proposal expected to be disclosed within 10 trading days [1] Group 2 - Haowei Technology, established in 2003 with a registered capital of 791.62 million yuan, provides digital solutions to global telecom operators, cloud infrastructure service providers, and enterprise clients [2] - The company has launched an innovative "Three-in-One" end-to-end intelligent computing supply solution, currently piloted in the education sector in Shanghai and the Sichuan-Chongqing region [2] - Deguote operates in the high-tech energy-saving and environmental protection equipment manufacturing sector, focusing on clean combustion and heat energy-saving solutions for industries such as chemicals and waste treatment [2] Group 3 - Deguote reported a revenue of 509 million yuan for 2024, a year-on-year increase of 64.21%, and a net profit of 96.71 million yuan, up 150.15% [3] - In Q1 2025, the company experienced a revenue decline of 31.19% year-on-year, with a net profit decrease of 53.24% [3] - The company indicated that its gross margin improvement is attributed to its ongoing international expansion, with overseas market gross margins maintaining around 50% [3]

Company Overview - The company has over 30 years of experience in the pharmaceutical industry in China, focusing on research-driven and market-oriented biopharmaceutical development[10]. - The group currently markets over 25 proprietary, generic, and licensed-in pharmaceutical products across Mainland China, Hong Kong, Macau, and Taiwan[11]. - The therapeutic areas of focus include cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics, with a strong project pipeline[12]. - The company has established partnerships with around 30 international companies for development and commercialization rights[11]. - The company is committed to maintaining a strong infrastructure in drug development, clinical development, regulatory compliance, manufacturing, sales, and marketing[11]. Manufacturing and Operations - The manufacturing plant in Hefei, Anhui Province, operates four GMP-compliant workshops for various pharmaceutical products, while the Guangzhou site includes solid dosage production lines for tablets and capsules[13]. - The Nansha manufacturing facilities, established in 2015, are now contributing meaningfully to revenue with advanced production capabilities[40]. - The Hefei manufacturing facility recorded a 34% increase in total production volume in 2024, with a 77% surge in pre-filled syringe production volume[69]. Financial Performance - Revenue for 2024 reached HK$1,399,969, representing a 32.9% increase from HK$1,053,034 in 2023[21]. - Gross profit increased by 36.6% to HK$753,355 from HK$551,311 in the previous year[21]. - Profit attributable to the owners of the Company surged by 457.5% to HK$93,099 compared to HK$16,698 in 2023[21]. - Basic earnings per share rose to 15.81 HK cents, a 456.7% increase from 2.84 HK cents in 2023[21]. - Total dividend per share increased by 150.0% to 4.5 HK cents from 1.8 HK cents in 2023[21]. - The dividend payout ratio decreased to 28.5% from 63.4% in the previous year[21]. Research and Development - The drug development pipeline includes major therapeutic areas such as cardiovascular health, women's health, and oncology, with 4 projects currently under review by the CDE[44]. - Research and development expenses were reduced to HK$83.8 million in 2024 from HK$96.8 million in 2023, optimizing resource allocation[34]. - The Group is collaborating with Auransa Inc. to manufacture AU409, an AI-derived drug targeting advanced hepatocellular carcinoma, with the Phase I clinical trial expected to conclude by Q2 2025[46]. - The Group's R&D efforts have led to the development of new products, including Sokazoli monoclonal antibody injection and INOmax® inhaled nitric oxide gas[180]. Product Portfolio - The Company has a diverse product portfolio including proprietary and licensed-in products across various markets[18][19]. - New products include Livaracine® and Nadroparin Calcium Injection, targeting blood clots and deep vein thrombosis[18]. - The Group's new product Socazolimab Injection (善克鈺®) and Adapalene and Clindamycin Combination Gel (馥霖安®) are expected to drive future growth after being listed in procurement platforms[90]. Market Strategy - The sales and distribution network covers most provinces and cities in Mainland China, utilizing both direct and channel sales[13]. - The company aims to expand its market presence and enhance its product offerings through ongoing research and development initiatives[12]. - The Group's strategic direction includes expanding its market presence and enhancing its R&D capabilities through collaboration with renowned scientists[185]. Corporate Governance and Leadership - The company has a strong leadership team with extensive experience in finance and management, including key personnel like Li Xiaofang and Li Yini, who have been with the company since 1997[148][149]. - The company is focused on maintaining high standards of corporate governance and financial transparency, which is critical for investor confidence and long-term success[156][162]. - The Group established a Risk Control Centre in 2020 to enhance compliance and audit operations[165]. Challenges and Future Outlook - The Group's strategic execution and commitment to innovation have positioned it for long-term growth despite challenges from legacy product agreements and the scaling of new products[58]. - The Group is focusing on cost-control measures and enhancing operational efficiency to navigate challenges in China's pharmaceutical industry[140]. - The Group's commitment to cost-saving measures aims to enhance operational performance and profitability while managing expenditures effectively[64].

Financial Performance - Revenue for the year ended December 31, 2024, reached HKD 1,399,969, representing a 32.9% increase from HKD 1,053,034 in 2023[2] - Gross profit increased by 36.6% to HKD 753,355, up from HKD 551,311 in the previous year[2] - Profit attributable to owners of the company surged by 457.5% to HKD 93,099, compared to HKD 16,698 in 2023[2] - Basic and diluted earnings per share rose by 456.7% to HKD 15.81, up from HKD 2.84 in the prior year[2] - Operating profit for the year was HKD 113,142, significantly up from HKD 43,553 in 2023[4] - The total comprehensive income for the year was HKD 124,663,000, compared to HKD 127,582,000 in the previous year, a slight decrease of about 2%[8] - The company reported a profit of HKD 93,099,000 for the year, which is a recovery from a loss in the previous period[8] - The group recorded revenue of HKD 1,399,969,000 for the fiscal year ending December 31, 2024, a significant increase of 32.9% compared to HKD 1,053,034,000 in the previous year[33] - Gross profit reached HKD 753,355,000, up 36.6% from HKD 551,311,000 last year, with a gross margin improvement from 52.4% to 53.8%[36] - The group achieved a net profit attributable to shareholders of HKD 93,099,000 for 2024, a substantial improvement from HKD 16,698,000 in 2023[39] Dividends - The board proposed a final dividend of HKD 0.025 per share, an increase from HKD 0.01 in 2023[2] - The company declared an interim dividend of HKD 0.020 per share, totaling HKD 11,777,000, compared to HKD 0.008 per share and HKD 4,711,000 in the previous year[26] - The company plans to propose a final dividend of HKD 0.025 per share, totaling HKD 14,721,000, compared to HKD 5,888,000 in the previous year[27] - The board of directors proposed a final dividend of HKD 0.025 per share for the year 2023, an increase from HKD 0.010 per share in the previous year[55] - The final dividend will be distributed on June 16, 2025, pending shareholder approval at the annual general meeting[59] Assets and Liabilities - Non-current assets decreased to HKD 1,833,281 from HKD 2,234,040 in 2023[6] - Current liabilities increased to HKD 771,254 from HKD 648,818 in the previous year[6] - Total equity attributable to the company's owners decreased from HKD 2,038,955,000 in 2023 to HKD 1,651,799,000 in 2024, a decline of approximately 19%[7] - Total equity decreased from HKD 1,960,598,000 in 2023 to HKD 1,548,906,000 in 2024, representing a decline of about 21%[8] - The total assets of the group for 2024 were HKD 2,617,866,000, a decrease from HKD 2,890,667,000 in 2023[19] - The total liabilities for 2024 increased to HKD 1,068,960,000 from HKD 930,069,000 in 2023[19] Research and Development - Research and development expenses increased to HKD 83,829,000 in 2024 from HKD 96,804,000 in 2023, indicating a focus on innovation[14] - The group invested a total of HKD 193,085,000 in research and development, representing 13.8% of annual revenue, down from 20.9% in the previous year[37] - The company is currently developing multiple assets in key therapeutic areas including cardiovascular health, women's health, pediatrics, rare diseases, dermatology, and obstetrics, with several projects in late-stage development[42] Market and Sales Performance - Over 90% of the group's revenue in 2024 was derived from operations in the People's Republic of China[18] - The sales of newly introduced products increased significantly, with sales of "布累迪寧®" rising by 24.5% to HKD 133,800,000 and "芮舒延®" soaring by 143.4% to HKD 20,700,000[34] - The group’s proprietary products showed strong performance, with sales of "立騰菁®" increasing by 130.4% to HKD 192,700,000[34] Operational Challenges and Strategies - The company is facing significant challenges due to the inclusion of products in the national medical insurance plan, leading to profit declines and increased operational costs[53] - The company is implementing strict cost control measures to enhance operational efficiency in response to profit pressure from drug procurement policies[54] - The company continues to focus on innovation and optimizing its product portfolio to overcome challenges and ensure long-term growth[35] Corporate Governance - The annual general meeting is scheduled for May 22, 2025, to discuss shareholder matters[56] - The company will suspend share transfer registration from May 19, 2025, to May 22, 2025, to determine eligible shareholders for the annual general meeting[57] - The independent auditor has reviewed the preliminary performance announcement, confirming consistency with the audited financial statements[65] - The company will publish its annual report for the year ending December 31, 2024, on its website and the designated exchange website[66] - The board of directors includes Chairperson Li Xiaofang and Executive Director Li Yeni[67] - The company has independent non-executive directors including Chen Youzheng, Jiang Qihua, and Zhan Huaqiang[67] - The meeting was held on March 27, 2025, indicating ongoing corporate governance and transparency efforts[67]

Financial Performance - The Group's revenue for the first half of 2024 reached HK$658,345,000, a significant increase of 28.5% compared to HK$512,308,000 in the same period of 2023[4] - Gross profit for the first half of 2024 was HK$350,595,000, reflecting a 23.2% increase from HK$284,463,000 in the first half of 2023, despite a decrease in gross profit margin to 53.3%[7] - Net profit attributable to the owners of the Company was HK$62,478,000, a remarkable increase of 287.7% from HK$16,117,000 in the first half of 2023[10] - Profit for the period increased significantly to HK$54,869,000, compared to HK$20,909,000 in 2023, marking a 162.5% year-over-year growth[115] - Basic and diluted earnings per share for the period were both HK$10.61, compared to HK$2.74 in the previous year, reflecting a substantial increase[115] Revenue Composition - Notable product sales growth included Treprostinil Injection at 56.8%, Teglutik® at 187.2%, and Trittico® at 232.1%, with Nadroparin Calcium Injection experiencing a tenfold increase[4] - The contribution from licensed-in products decreased to 38.9% of revenue, down from 46.9% in the same period of 2023, while proprietary and generic products increased to 61.1% from 53.1%[6] - The Group's strategic shift towards proprietary and generic products is driven by changes in the market environment[6] Expenses and Cost Management - Research and development expenses totaled HK$84,713,000, a decrease of 25.5% from HK$113,634,000 in the same period last year, representing 12.9% of revenue[9] - Selling and distribution expenses rose to HK$172,265,000, an increase of 17.2% compared to HK$146,931,000 in the same period last year, with a selling expenses to revenue ratio of 26.2%[10] - The Group faces challenges from increased competition and rising operating costs, necessitating strategic management and focus[30] - To address these challenges, the Group will implement stringent cost control measures and emphasize efficiency across the value chain, particularly in sales and R&D functions[33] Research and Development - The Group is focusing on optimizing resource allocation among prioritized R&D projects while maintaining cost-saving efforts[9] - The oncology pipeline includes 6 innovative treatments and 4 generics, with a recent submission for indication expansion of Socazolimab Injection to the NMPA based on Phase III trial results for extensive-stage small-cell lung cancer[18] - The Group maintains a strong project pipeline, with the NDA for Cetraxal® Plus submitted in 2023 and currently under review by the CDE[14] Financial Position - As of June 30, 2024, the Group's current ratio improved to 1.10 from 1.01 on December 31, 2023, indicating better liquidity[44] - The Group's net debt position increased to HK$36,488,000 as of June 30, 2024, compared to HK$19,563,000 on December 31, 2023[44] - Total equity attributable to the owners of the Company decreased from HK$2,038,955,000 as of December 31, 2023, to HK$1,713,545,000 as of June 30, 2024, a decline of approximately 15.9%[121] Share Options and Employee Compensation - The company adopted a new share option scheme in May 2022, replacing the previous scheme that expired in May 2022[51] - The share options granted under the 2012 scheme before its expiry remain valid, subject to the same terms and conditions[52] - The company is committed to ensuring that it does not face foreign exchange issues when dealing with its earnings and costs denominated in various currencies[50] - The share option schemes are designed to incentivize employees and align their interests with those of shareholders[51] Dividends and Shareholder Returns - The company reported an interim dividend of HK$0.020 per share, an increase from HK$0.008 in 2023, reflecting a 150% rise[96] - The company paid dividends amounting to HK$5,888,000 during the period, consistent with the previous year[125] Financial Risks and Management - The Group's activities expose it to various financial risks, including market risk, credit risk, and liquidity risk, with no significant changes in risk management policies since the year-end[139] - The Group's financial risk management practices are designed to mitigate exposure to identified financial risks[140] Corporate Governance - The company has complied with the Corporate Governance Code throughout the six months ended June 30, 2024[103] - The company’s board of directors includes both executive and non-executive members, ensuring diverse governance[103] - The company is committed to reviewing its corporate governance practices to ensure ongoing compliance[103]

Financial Performance - For the six months ended June 30, 2024, the company's revenue was HKD 658,345,000, an increase of 28.5% compared to HKD 512,308,000 in the same period last year[3]. - Gross profit for the same period was HKD 350,595,000, reflecting a 23.2% increase from HKD 284,463,000 year-on-year[4]. - The profit attributable to the company's owners surged to HKD 62,478,000, marking a significant increase of 287.7% from HKD 16,117,000 in the previous year[5]. - Basic and diluted earnings per share rose to HKD 10.61, up 287.2% from HKD 2.74 in the same period last year[1]. - The interim dividend per share was increased to HKD 2.00, representing a 150.0% rise from HKD 0.80 in the previous year[1]. - The company reported a profit of HKD 54,869,000 for the six months ended June 30, 2024, compared to HKD 20,909,000 for the same period in 2023, representing a significant increase of 161.5%[16]. - Basic earnings per share increased to HKD 10.61 for the six months ended June 30, 2024, compared to HKD 2.74 for the same period in 2023[15]. - The operating profit for the period was HKD 68,134,000, up from HKD 33,067,000 in the previous year, indicating a 106% growth[26]. Revenue Sources - Sales from newly introduced products accounted for 38.9% of total revenue, down from 46.9% in the same period last year, while sales from proprietary and generic products increased to 61.1% from 53.1%[4]. - The group reported segment revenue of HKD 402,343,000 for the six months ended June 30, 2024, compared to HKD 272,091,000 for the same period in 2023, representing a 48% increase[26]. - The company generated over 90% of its revenue from operations in the People's Republic of China, indicating a strong market presence[28]. Expenses and Cost Management - Research and development expenses decreased by 25.5% to HKD 84,713,000, representing 12.9% of revenue compared to 22.2% in the previous year[5]. - Sales and distribution expenses increased by 17.2% to HKD 172,265,000, with the ratio to revenue decreasing to 26.2% from 28.7% year-on-year[5]. - The company is implementing strict cost control measures to enhance profitability and operational efficiency in response to rising operational costs and inflation pressures[14]. - Research and development expenses increased to HKD 90,082,000 from HKD 58,978,000, reflecting a 53% rise year-over-year[26]. Asset and Liability Management - Non-current assets decreased to HKD 1,851,952,000 as of June 30, 2024, down from HKD 2,234,040,000 at the end of 2023, reflecting a decline of 17.1%[17]. - Current assets increased to HKD 696,760,000, up from HKD 656,627,000, indicating a growth of 6.5%[17]. - Total equity attributable to the owners of the company decreased to HKD 1,713,545,000 from HKD 2,038,955,000, a decline of 16.0%[18]. - The company’s total liabilities decreased to HKD 288,788,000 from HKD 281,251,000, reflecting a slight increase of 2.0%[18]. - Trade receivables increased significantly to HKD 127,271,000 from HKD 84,590,000, representing a growth of 50.5%[17]. Cash Flow and Investments - Operating cash generated for the six months ended June 30, 2024, was HKD 67,203,000, compared to HKD 44,205,000 for the same period in 2023, representing a 52% increase[20]. - Net cash generated from operating activities for the six months ended June 30, 2024, was HKD 58,976,000, up from HKD 39,063,000 in 2023, reflecting a 51% growth[20]. - Cash used in investing activities for the six months ended June 30, 2024, was HKD 65,206,000, a decrease from HKD 88,587,000 in 2023, indicating a 26% reduction[20]. - Cash and cash equivalents increased by HKD 21,769,000 for the six months ended June 30, 2024, compared to a decrease of HKD 28,782,000 in the same period of 2023[20]. Dividends and Shareholder Returns - The company declared an interim dividend of HKD 0.020 per share for the six months ended June 30, 2024, compared to HKD 0.008 per share in 2023, totaling HKD 11,777,000[33]. - The company paid dividends of HKD 5,888,000 for both the six months ended June 30, 2024, and 2023, indicating stable dividend distribution[20]. Corporate Governance and Compliance - The company has not early adopted any new or revised Hong Kong Financial Reporting Standards that may significantly impact its financial performance[23]. - The company’s accounting policies remain consistent with those used in the annual financial statements for the year ended December 31, 2023[22]. - The company continues to comply with the corporate governance code as per the listing rules[52]. Product Development and Market Strategy - The company has submitted a new drug application for "Cetraxal® Plus" in 2023, which is currently under review by the drug evaluation center[7]. - The company is expanding production capacity for "Lichangqing®" and "Litengqing®" with a new pre-filled production line expected to be operational in 2024[6]. - The company is actively developing multiple assets in key therapeutic areas, including cardiovascular, women's health, and oncology, with a strong pipeline of innovative drugs[8][9]. - The sales and marketing team has successfully adjusted sales growth trajectories, with ten products included in the updated national medical insurance catalog[13].